Development of an HSV-1 neutralization test with a glycoprotein D specific antibody for measurement of neutralizing antibody titer in human sera
- Yong Luo†1,
- Dan Xiong†1, 2,
- Huan-Huan Li1, 2,
- Sheng-Ping Qiu1, 2,
- Chao-Long Lin1, 2,
- Qin Chen1, 2,
- Cheng-Hao Huang1Email author,
- Quan Yuan1,
- Jun Zhang1 and
- Ning-Shao Xia1, 2Email author
© Luo et al. 2016
Received: 12 January 2016
Accepted: 15 March 2016
Published: 18 March 2016
Investigating the neutralizing antibody (NAb) titer against HSV-1 is essential for monitoring the immune protection against HSV-1 in susceptible populations, which would facilitate the development of vaccines against herpes infection and improvement of HSV-1 based oncolytic virotherapy.
In this study, we have developed a neutralization test based on the enzyme-linked immunospot assay (ELISPOT-NT) to determine the neutralizing antibody titer against HSV-1 in human serum samples. This optimized assay employed a monoclonal antibody specifically recognizing glycoprotein D to detect the HSV-1 infected cells. With this test, the neutralizing antibody titer against HSV-1 could be determined within one day by automated interpretation of the counts of cell spots. We observed good correlation in the results obtained from ELISPOT-NT and plaque reduction neutralization test (PRNT) by testing 22 human serum samples representing different titers. Moreover, 269 human serum samples collected from a wide range of age groups were tested, the average neutralizing antibody titer (log2NT50) was 8.3 ± 2.8 and the prevalence of NAbs was 83.6 % in this cohort, it also revealed that the average neutralizing antibody titer in different groups increased with the age, and no significant difference in neutralizing antibody titers was observed between males and females.
These results prove that this novel assay would serve as an accurate and simple assay for the assessment of the neutralizing antibody titers against HSV-1 in large cohorts.
KeywordsHerpes Simplex virus type I Neutralizing antibody ELISPOT Cohort study
Herpes simplex virus type 1 (HSV-1) is the causative pathogen of orolabial herpes, one of the most prevalent oral transmitted diseases worldwide. More than 60 % of people worldwide were infected with HSV-1 during their lifetime [1, 2]. HSV-1 infection may become chronic, which may lead to oral vesicular lesions at the sites of primary infection, and is recognized as a significant cause of morbidity and mortality in the newborn and immunocompromised individuals [3, 4]. Moreover, HSV-1 also accounts for a substantial proportion of genital herpes infections . HSV-1 viruses cannot be eradicated, which can establish latency for lifelong in sensory ganglia following initial acquisition, thus the majority of people infected with HSV-1 stay in a state of “asymptomatic”.
Generation of humoral immunity and cellular immunity was indicated to play a crucial role in controlling herpes virus shedding [6, 7]. Neutralizing antibodies (NAbs) to viral glycoproteins were elicited in response to HSV-1 infection , which may provide some certain protection against HSV-1 acquisition or reduce the severity of HSV-1 related diseases [9, 10]. Surveillance of seroprevalence against HSV-1 in susceptible populations is essential for monitoring the seroconversion rates in countries where HSV-1 is endemic to evaluate the effectiveness of vaccination and anti-viral therapy against herpes infection, especially to HSV-2 infection. Moreover,HSV-1 based oncolytic virus, which usually contain attenuated modifications and expresses multiple therapeutic genes, had been proved to be good therapeutic gene therapy vectors for treating central nervous disease and multiple cancers [11, 12]. NAbs against HSV-1 are one of the barriers oncolytic viruses encounter during viral replication in vivo. However, it is largely unknown whether the circulating NAbs in cancer patients will restrict the efficacy of HSV-1 based virotherapy, especially when the viruses are administrated through intravenous delivery . Thus, it’s intriguing for us to know the average NAb titers in general population, the relationship between HSV-1 serostatus and NAb titers, and which amount of NAbs will affect the efficacy of HSV-2 vaccine, as well as HSV-1 based oncolytic virotherapy.
Conventional assays previously employed to quantitatively determine the NAb titers against herpes virus include the cytopathic effect-based neutralization test (CPE-NT) and the plaque reduction neutralization test (PRNT) [14, 15], which are widely accepted and considered the laboratory gold standard test. However, these assays are arduous and time consuming, requiring long time of infections and plenty of manual counting jobs. Thus, these tests may not be feasible to screen large cohorts from clinical trials or epidemiology studies. Therefore, a high-throughput assay is needed for rapid and precise evaluation of the NAb titers against HSV-1.
Then ELISPOT is a powerful tool for detection and quantification of single secreting cell in a 96 well plate. The ELISPOT with high sensitivity has been successfully applied to detect low frequency cells secreting cytokines, antigens and antibodies, which is widely used in immunological studies and vaccine development [16–18]. Recently, the ELISPOT assay has been adapted to measure the NAb titers against various viruses, such as HIV, enterovirus and dengue virus [19–21]. In this study, we established a high-throughput, quantitative and reliable ELISPOT-based neutralization test (ELISPOT-NT) to rapidly measure the neutralizing antibody titer against HSV-1 in human serum samples. Employing this test, we depicted the prevalence of NAbs among a cohort with wide range of ages.
Characterization of the MAbs in this study
Influence of infection parameters on the detection of cells infected with HSV-1
Feasibility of the ELISPOT-NT
Based on the previous findings, we next evaluated the feasibility of ELISPOT based neutralizing test (ELISPOT-NT) using 2G5 antibody on determining the neutralizing antibody titers of human serum samples. To verify this, we first selected a NAb-positive serum sample, a NAb-negative serum sample and a negative control (PBS) for testing. As shown in Fig. 3a, it was found that the spot counts decreased along with the increasing folds of dilution in the NAb-positive serum, while there was no any inhibition effect in the NAb-negative serum.
Moreover, it was necessary to investigate whether the neutralizing antibody titers of human serum samples can be reliably measured by use of ELISPOT-NT under different experimental variations, such as infectious dose. Thus, three independent serum samples were measured with the ELISPOT-NT under different infectious doses. As shown in Fig. 3b, c and d, the results obtained from the ELISPOT-NT were repeatable and consistent, the infectious doses did not influence the neutralizing antibody titers (NT50) of three independent serum samples. Due to the limit of serum usage, determining the neutralizing antibody titer become difficult for serum samples with NT50 below 5. Thus, if the NT50 of a serum sample (both IgG and IgM negative) was below 5, it would be defined as negative (unpublished data).
Correlation between PRNT and ELISPOT-NT
Characteristics of study participants
Baseline characteristics of a cohort from general population in Xiamen
HSV-1 seroprevalence (%)
HSV-1 NAb prevalence (%)
Average NAb titers (log2NT50)
41 (15.2 %)
29.3 % (17.6 %-44.5 %)*
31.7 % (19.6 %-47.0 %)*
4.4 ± 3.1
47 (17.5 %)
74.5 % (60.5 %-84.8 %)*
74.5 % (60.5 %-84.8 %)*
7.5 ± 3.1
41 (15.2 %)
92.7 % (80.6 %-97.5 %)
95.1 % (83.9 %-98.7 %)
9.2 ± 1.6
49 (18.2 %)
91.8 % (80.8 %-96.8 %)
97.9 % (89.3 %-99.6 %)
9.1 ± 1.4
48 (17.8 %)
91.7 % (80.5 %-96.87 %)
97.9 % (89.1 %-99.6 %)
9.5 ± 1.7
97.7 % (87.9 %-99.6 %)
100 % (91.8 %-100 %)
9.8 ± 1.6
126 (46.8 %)
83.3 % (75.9 %-88.8 %)
84.9 % (77.7 %-90.1 %)
8.2 ± 2.8
143 (53.2 %)
76.9 % (69.4 %-83.1 %)
82.5 % (75.5 %-87.9 %)
8.4 ± 2.9
79.9 % (74.7 %-84.3 %)
83.6 % (78.8 %-87.6 %)
8.3 ± 2.8
The prevalence of NAbs against HSV-1 in general population
Although PRNT has been accepted worldwide as the gold standard for measuring NAb titers against viruses, it is also known that some deficiencies of PRNT, such as time-consuming and labor-intensive, restricts the usage of this method in high throughput screening. Therefore, some novel assays for titration of NAbs had been developed, such as neutralization assays based on a reporter gene, flow cytometry and ELISPOT [22, 23]. Recently, ELISPOT-NT have showed some advantages in assessing the NAb titer with higher sensitivity and better concordance with PRNT than other assays, which relied on the antibodies to recognize the infected cells that express specific viral proteins [16, 20, 21]. Usually, the viral proteins selected need to be abundantly expressed during the initial infection and be accessible by the antibodies. The secondary antibodies coupled to horseradish peroxidase can further improve the sensitivity of the assay by enzyme amplification effect. To our knowledge, a feasible ELISPOT-NT for detecting NAbs against herpes virus had not been established before. Therefore, we screened a panel of MAbs against HSV-1 to test if they can detect the HSV-1 infected cells with high specificity and sensitivity. We selected an antibody, named 2G5 and specifically recognized the glycoprotein D, which could be used for detection of HSV-1 infection. Based on this antibody, we established a quantitative and reliable ELISPOT assay for determining the NAb titers. Factors that may impact the accuracy of this assay has been systematically evaluated, it turns out that this assay is reproducible and consistent within a broad linear range of infectious doses. The theory that the neutralizing antibody titers are not impacted by the infectious doses is simply the reflection of “the percentage law”, which states that if the antibody concentration is way above the virus concentration, a given concentration of antibody neutralizes the same relative proportion of virus infectivity irrespective of the quantity of virus present [24, 25].
Taking the results of PRNT as the reference, ELISPOT-NT gave similar results in testing the neutralizing antibodies among all representing 22 sera. A good correlation (R 2 = 0.9682; P < 0.0001) was observed between PRNT and ELISPOT-NT. Compared with the PRNT, the ELISPOT-NT is an efficient neutralization test with several advantages: it is rapid and the whole procedure can be finished within 24 h, from the time cells are seeded into plates until the data is analyzed; it is more flexible, the infectious dose within a relatively wide range has little influence on the results; it is precise, the titration of NAbs is repeatable and consistent with the result obtained from PRNT; it is high throughput, thousands of samples can be tested in a single run. Recently, Blevins et al. reported a high throughput assay to quantify the NAb titer against herpes simplex viruses in human serum samples, this assay employed a ELVIS cell line, which was stably transfected with the LacZ gene under the control of the HSV ICP6 promoter . Under the circumstance of HSV infection, the LacZ protein was expressed and could be detected by addition of CPRG substrate. The NAb titer could be consistently quantified using this assay, but the correlation data between this assay and classical PRNT assay was not reported. ELISPT-NT requires less operation time than ELVIS cell-based assay (24 h vs. 46 h). However, both these two assays are not fully automated, require 2 ~ 3 h’s plate manipulation.
Protection against HSV-1 infection correlates well with the antibody levels, whereas the exact role for NAbs in controlling HSV-1 infection and reflecting T-cell responses remains elusive [27, 28]. ELISPOT-NT shows potential as a powerful method for screening neutralization activities of large numbers of serum samples. From a cohort of general population with different ages in Xiamen, we observed a significant increasing trend in the average NAb titers along with the age, suggesting that the general population were suffered from lifelong challenge by HSV-1 virus. For the first time, we found that HSV-1 serologic status was not fully related to the NAb titers, 10 individuals tested with HSV-1 IgG negative by ELISA were presenting with NAb positive, which implied that the different clinical significances for anti-HSV-1 IgG level and the neutralizing antibody titers. A reasonable explanation is there are several types of neutralizing antibodies against more than five HSV-1 proteins, but the current HSV-1 IgG ELISA kits may only target one or two major ones. Thus, further learning the level of NAbs response to infection in general populations is important for understanding how these protective Abs may affect the HSV-1 recurrence, including their significance in the development of vaccines against herpes virus.
Although HSV-1 harbors a high similarity with HSV-2, the biologic characteristics of them are obviously different. The development of a vaccine to prevent HSV-2 infection had been failed due to inconsistently effective results in people with different serologic status of herpes virus acquired from the clinical trails . Interestingly, in women who were negative for antibodies to both HSV-1 and HSV-2, HSV-2 gD-2 vaccine seemed to protect a small proportion of them from HSV-1 infection rather than HSV-2 infection . However, the factor contributes to this type-specific protection remains largely unknown. A reasonable explanation is there are some differences in the antibody activity against HSV-1 and HSV-2. To prove this point, the NAb titers of vaccine-induced antibodies against HSV-1 should be determined. This setback in the development of HSV-2 vaccine provides some important information for future design of new generation vaccines, which can elicit higher titers of NAbs than those induced by natural infection, or induce stronger T cell response .
The HSV-1 based oncolytic virus, Talimogene laherparepvec, had been confirmed to be therapeutically potent in a phase 3 trial of treating metastatic melanoma and got the approval of FDA into market in 2015 [30, 31]. Additionally, more than 5 HSV-1 based oncolytic viruses had also been proved to be safe and effective in the different clinical trials against multiple cancers [32–35]. NAbs against HSV-1 are one of the barriers viruses encounter during viral replication in vivo . However, it is largely unknown whether the circulating NAbs in cancer patients will restrict the efficacy of HSV-1 based oncolytic virotherapy, especially when the viruses are administrated through intravenous delivery . A survey we conducted in the general population by testing the NAb titers against HSV-1 revealed that the average NAb titers were 8.3 ± 2.8, and the prevalence of NAbs against HSV-1 increased with age, with an older population (above 50 years old) having the highest NAb titers (the average neutralizing antibody titers was 9.8 ± 1.6). As we know, older adults have a higher risk for cancer, it’s intriguing for us to know whether the NAbs will reduce the efficacy of oncolytic virus mediated cancer remission in patients with higher NAb titers, especially among those with elder ages. Further studies are still needed to design for supporting the importance of NAbs against HSV-1 so as to broaden the application of this ELISPOT-NT.
We established an HSV-1 neutralization test based on the enzyme-linked immunospot assay (ELISPOT-NT) to determine the neutralizing antibody titer against HSV-1 in human serum samples. In this test, we employed a monoclonal antibody specifically recognizing glycoprotein D to detect the cells that were infected with HSV-1. Using this high-throughput test, the neutralizing antibody titers against HSV-1 from human sera can be detected precisely within 24 h. The stability and consistency of this assay was systematically evaluated in parallel with a conventional neutralization test, a good correlation in determining the neutralizing antibody titers was observed. Through a cohort study, in the general population consisting of 269 healthy individuals in Xiamen City of China, we observed significant differences in neutralizing antibody titers across the different ages by using this test. We also demonstrated that the anti-HSV-1 IgG level was not closely associated with neutralizing antibody titers. The ELISPOT-NT test could serve as an accurate and simple assay for large cohort studies in assessing the role of the neutralizing antibody titers against HSV-1 on the development of vaccines against herpes infection and HSV-1 based oncolytic virotherapy.
Cells and Viruses
Human U-2 OS cells and HEK 293 T cells were purchased from American Type Culture Collection (ATCC) and maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 10 % fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin. U-2OS cells are widely recognized as a common cell model for HSV-1 titration and functional study of HSV-1 infection [37–39]. Besides, U2OS cells are a good cell option for spot detection due to their characteristics of big size and round shape. Herpes simplex virus 1, KOS strain, was purchased from ATCC. Viruses were propagated and titrated in U-2 OS cells, and kept in storage at −80 °C.
Plasmids and transfection
Lentivirus vector was purchased from Addgene. The HSV-1 glycoprotein genes (gB ~ gN) were amplified from KOS genome and subcloned into lentivirus vector. Lentivirus constructs with glycoprotein-expressing genes (plv-gB ~ gN) were co-transfected respectively in 293 T cells along with helper vectors using Lipofectamine 2000 according to the manufacturer’s instructions (Invitrogen). For viral transduction, the U-2 OS cells were transduced with the medium containing lentivirus harvested 48 h after transfection, in the presence of 6 μg/mL polybrene. Stable clones were selected under the pressure of puromycin.
Human serum samples
Serum samples from 269 healthy individuals with various ages were collected at random times throughout 2014 from the Center for the Disease Control and Prevention (CDC) of Xiamen. All study participants resided in the city of Xiamen.
Total antibodies against HSV-1 in this cohort was determined by HSV-1 IgG ELISA kit (Wantai Bio). Tests were performed as described in the manufacturer’s instruction manuals. In brief, 100 μl of a 5-fold diluted serum sample was added to the microplate well and incubated at 37 °C for 1 h. After stringent washing, and then 100 μl of HRP-conjugated secondary antibody was added and incubated 37 °C for 0.5 h. The wells were washed three times, 100 μl of TMB substrate was added and incubated 15 min at room temperature. Subsequently, 50 μl of stop solution was added and the absorbance value (expressed as optical density [OD]) was read by an ELISA plate reader. The result of tests were defined as follows: OD values > 0.1, positive; OD values ≤0.1, negative, the tests would be repeated by using 100 μl serum samples.
For the preparation of anti-HSV-1 monoclonal antibodies, six-week-old female BALB/c mice were immunized with KOS viruses by standard prime and boost vaccination procedure. The hybridoma cells were obtained following the protocol reported previously . The positive clones were screened and selected by indirect ELISA coated with KOS viruses and immunostaining assay that the antibodies can specifically bind to the HSV-1 infected cells. MAbs were prepared by ascites production and purified by using protein G chromatography according to the manufacturer’s instructions.
U-2 OS cells were seeded in 96-well plates at a density of 2 × 104 cells per well and incubated for 6 h at 37 °C in 5 % CO2 until the cells became monolayer. 1 × 104 PFU viruses in a volume of 100 μL were added to the monolayer cells and incubated for 14 h. After infection, the cells were fixed with 1 % paraformaldehyde in PBS for 5 min and followed by permeabilization with 0.1 % Triton X-100 in PBS at room temperature for 5 min. Next, each diluted monoclonal antibody (10 μg/mL) was added and incubated at 37 °C for 1 h. After reaction with the HRP-conjugated secondary antibody (1:2000), the spots were developed in TMB substrates (Sigma) within 15 min. Last, the plates were spin dried and counted using ImmunSpot@S5 UV Analyzer (Cellular Technology Limited). Each antibody was repeated in triplicate wells and each test was carried out in duplicate or triplicate. An irrelevant antibody, which specifically recognized HBV envelope protein, was used as a negative control.
Western blotting was done as previously described . In brief, cells were lysed in lysis buffer (20 mM Hepes, 1 mM EGTA, 5 mM MgCl2, 100 mM NaCl, 4 mg/mL Decyl-beta-d-maltopyranoside, 10 % glycerol and protease inhibitor cocktail). Cell lysates were separated by SDS-PAGE and transferred onto a nitrocellulose membrane. After membranes were blocked with 5 % BSA for 1 h, they were probed with indicated primary antibodies (8 μg/mL) overnight at 4 °C, followed by incubation with the HRP-conjugated secondary antibodies for 1 h at room temperature, and finally visualized with the Lumi-LightPLUS Western blotting Substrate (Roche).
Standard immunofluorescence staining was performed as previously described . In brief, cells on the glass slides were fixed with 1 % paraformaldehyde and permeabilized by 0.1 % Triton X-100. After blocked with 5 % normal goat serum in PBS for 1 h, the slides were stained with primary antibody 2G5 (8 μg/mL) overnight at 4 °C, then incubated with FITC conjugated secondary antibody before examination using confocal microscope.
Plaque reduction neutralization test
U-2 OS cells were seeded in 6 cm dishes at a density of 1 × 106 cells per well and cultured for 2 days at 37 °C in 5 % CO2 until the cells became monolayer. All serum samples were heat inactivated at 56 °C for 30 min prior to testing. The test serum samples were first diluted 20-fold in DMEM containing 10 % heat inactivated FBS, followed by two-fold serial dilutions from 1:40 to 1:10240. An equal volume of viral dilution, containing 100 PFU viruses, was mixed with the diluted serum and incubated at 37 °C in 5 % CO2 for 1 h. Then the total mixture in a volume of 0.5 mL per dish was added evenly to the U-2 OS cells and incubated for 1.25 h. During the incubation, the infected dishes were shaken gently every 15 min. After the initial infection, the inoculums were removed and 4 mL fresh culture medium were added to facilitate the viral entry. After another 2 h incubation, the cell monolayers were overlaid with 10 mL of 2 % methylcellulose medium and then incubated at 37 °C in 5 % CO2 for 3 days. Last, the dishes were stained with 5 mL of 0.01 % neutral red for overnight, then the plaques were counted by use of a white-light transilluminator manually. Virus control wells were infected with the same amount of virus as the testing wells mixed with serially diluted serum. Each serum dilution was repeated in triplicate wells and each test was carried out in duplicate or triplicate. The raw data of each sample by PRNT method was calculated in a formula as follows: % reduction = 100 × [1-(average plaque counts for each dilution/average plaque counts for virus control) . If the % reduction were below 50 %, the serum samples were retested by starting a dilution from 5-fold.
ELISPOT based neutralization test
U-2 OS cells were seeded in 96-well plates at a density of 2 × 104 cells per well and incubated for 6 h at 37 °C in 5 % CO2 until the cells became monolayer. Serial dilutions of serum samples were prepared as described for PRNT with minor modifications. 1 × 104 PFU viruses in a volume of 50 μL were mixed with an equal volume of serial diluted serum samples and incubated at 37 °C in 5 % CO2 for 1 h in 96-well plates with U bottom shape. Then the mixture was added to the monolayer cells and incubated for 14 h. The optimal infectious dose and incubation time were determined in preliminary experiments in order to acquire reliable spot counts. Then, standard ELISPOT procedure was performed as previously described. Each serum dilution was repeated in triplicate wells and each test was carried out in duplicate or triplicate. The reduction rate of the serum sample can be calculated in the same manner as for PRNT.
The 50 % inhibitory concentration (IC50) of each sample is defined as the highest dilution that gave 50 % plaque reduction. The neutralizing antibody titers can be interpreted as the highest serum dilution that neutralizes 50 % of the viruses (NT50), which was calculated by nonlinear, dose–response regression analysis using Graphpad Prism software. The correlation between the two methods was analyzed by linear regression using SPSS 16.0 software. The average NAb titers across different ages were compared using two-tailed Mann–Whitney U test. A P value of less than 0.05 was considered statistically significant, and the confidence interval (CI) was 95 %.
The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Human Ethics Committee of the Xiamen University. Informed consent was obtained from each patient. The use of mice was approved by the Institutional Animal Care and Use Committee at Xiamen University.
We thank Shou-jie Huang for his excellent assistance on statistical analysis.
This work was supported by grant 3502Z20131001 from the Science and Technology Project of Xiamen, grant 2014Y2004 from the Science and Technology Innovation platform of Fujian Province, grant 81571990 from the National Natural Science Foundation of China.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis. 2002;186 Suppl 1:S3–28.View ArticlePubMedGoogle Scholar
- Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999–2010. J Infect Dis. 2014;209:325–33.View ArticlePubMedGoogle Scholar
- Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Morrow RL, Ewell MG, Stokes-Riner A, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012;366:34–43.View ArticlePubMedPubMed CentralGoogle Scholar
- Siegal FP, Lopez C, Hammer GS, Brown AE, Kornfeld SJ, Gold J, Hassett J, Hirschman SZ, Cunningham-Rundles C, Adelsberg BR, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med. 1981;305:1439–44.View ArticlePubMedGoogle Scholar
- Lafferty WE, Downey L, Celum C, Wald A. Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J Infect Dis. 2000;181:1454–7.View ArticlePubMedGoogle Scholar
- Bukowski JF, Welsh RM. The role of natural killer cells and interferon in resistance to acute infection of mice with herpes simplex virus type 1. J Immunol. 1986;136:3481–5.PubMedGoogle Scholar
- Cheng H, Tumpey TM, Staats HF, van Rooijen N, Oakes JE, Lausch RN. Role of macrophages in restricting herpes simplex virus type 1 growth after ocular infection. Invest Ophthalmol Vis Sci. 2000;41:1402–9.PubMedGoogle Scholar
- Johnston C, Koelle DM, Wald A. HSV-2: in pursuit of a vaccine. J Clin Invest. 2011;121:4600–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Mester JC, Glorioso JC, Rouse BT. Protection against zosteriform spread of herpes simplex virus by monoclonal antibodies. J Infect Dis. 1991;163:263–9.View ArticlePubMedGoogle Scholar
- Bourne N, Pyles RB, Bernstein DI, Stanberry LR. Modification of primary and recurrent genital herpes in guinea pigs by passive immunization. J Gen Virol. 2002;83:2797–801.View ArticlePubMedGoogle Scholar
- Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 2002;9:967–78.View ArticlePubMedGoogle Scholar
- Lachmann RH, Efstathiou S. Gene transfer with herpes simplex vectors. Curr Opin Mol Ther. 1999;1:622–32.PubMedGoogle Scholar
- Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Schmidt NJ, Dennis J, Lennette EH. Plaque reduction neutralization test for human cytomegalovirus based upon enhanced uptake of neutral red by virus-infected cells. J Clin Microbiol. 1976;4:61–6.PubMedPubMed CentralGoogle Scholar
- Gerna G, Chambers RW. Varicella-zoster plaque assay and plaque reduction neutralization test by the immunoperoxidase technique. J Clin Microbiol. 1976;4:437–42.PubMedPubMed CentralGoogle Scholar
- Patton K, Aslam S, Lin J, Yu L, Lambert S, Dawes G, Esser MT, Woo J, Janetzki S, Cherukuri A. Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells. Clin Vaccine Immunol. 2014;21:628–35.View ArticlePubMedPubMed CentralGoogle Scholar
- Saletti G, Cuburu N, Yang JS, Dey A, Czerkinsky C. Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood. Nat Protoc. 2013;8:1073–87.View ArticlePubMedGoogle Scholar
- Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods. 1983;65:109–21.View ArticlePubMedGoogle Scholar
- Patiris P, Hanson C. Single-round HIV type 1 neutralization measured by ELISPOT technique in primary human cells. AIDS Res Hum Retroviruses. 2005;21:784–90.View ArticlePubMedGoogle Scholar
- Liu L, Wen K, Li J, Hu D, Huang Y, Qiu L, Cai J, Che X. Comparison of plaque- and enzyme-linked immunospot-based assays to measure the neutralizing activities of monoclonal antibodies specific to domain III of dengue virus envelope protein. Clin Vaccine Immunol. 2012;19:73–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Yang L, He D, Tang M, Li Z, Liu C, Xu L, Chen Y, Du H, Zhao Q, Zhang J, et al. Development of an enzyme-linked immunosorbent spot assay to measure serum-neutralizing antibodies against coxsackievirus B3. Clin Vaccine Immunol. 2014;21:312–20.View ArticlePubMedPubMed CentralGoogle Scholar
- de Alwis R, de Silva AM. Measuring antibody neutralization of dengue virus (DENV) using a flow cytometry-based technique. Methods Mol Biol. 2014;1138:27–39.View ArticlePubMedGoogle Scholar
- van Remmerden Y, Xu F, van Eldik M, Heldens JG, Huisman W, Widjojoatmodjo MN. An improved respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein expression and automated plaque counting. Virol J. 2012;9:253.View ArticlePubMedPubMed CentralGoogle Scholar
- Andrewes CH, Elford WJ. Observations on Anti-Phage Sera. I: “The Percentage Law”. The British Journal of Experimental Pathology. 1933;14:367–76.Google Scholar
- Klasse PJ, Sattentau QJ. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol. 2002;83:2091–108.View ArticlePubMedGoogle Scholar
- Blevins TP, Mitchell MC, Korom M, Wang H, Yu Y, Morrison LA, Belshe RB. Higher Throughput Quantification of Neutralizing Antibody to Herpes Simplex Viruses. PLoS One. 2015;10, e0144738.View ArticlePubMedPubMed CentralGoogle Scholar
- Egan KP, Wu S, Wigdahl B, Jennings SR. Immunological control of herpes simplex virus infections. J Neurovirol. 2013;19:328–45.View ArticlePubMedPubMed CentralGoogle Scholar
- Stanberry LR, Cunningham AL, Mindel A, Scott LL, Spruance SL, Aoki FY, Lacey CJ. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis. 2000;30:549–66.View ArticlePubMedGoogle Scholar
- Dropulic LK, Cohen JI. The challenge of developing a herpes simplex virus 2 vaccine. Expert Rev Vaccines. 2012;11:1429–40.View ArticlePubMedPubMed CentralGoogle Scholar
- Harrington KJ, Puzanov I, Hecht JR, Hodi FS, Szabo Z, Murugappan S, Kaufman HL. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther. 2015.Google Scholar
- Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015;33:2780–8.View ArticlePubMedGoogle Scholar
- Geevarghese SK, Geller DA, de Haan HA, Horer M, Knoll AE, Mescheder A, Nemunaitis J, Reid TR, Sze DY, Tanabe KK, Tawfik H. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther. 2010;21:1119–28.View ArticlePubMedPubMed CentralGoogle Scholar
- Markert JM, Razdan SN, Kuo HC, Cantor A, Knoll A, Karrasch M, Nabors LB, Markiewicz M, Agee BS, Coleman JM, et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 2014;22:1048–55.PubMedPubMed CentralGoogle Scholar
- Mace AT, Ganly I, Soutar DS, Brown SM. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck. 2008;30:1045–51.View ArticlePubMedGoogle Scholar
- Nakao A, Kasuya H, Sahin TT, Nomura N, Kanzaki A, Misawa M, Shirota T, Yamada S, Fujii T, Sugimoto H, et al. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Ther. 2011;18:167–75.View ArticlePubMedGoogle Scholar
- Vile R, Ando D, Kirn D. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Ther. 2002;9:1062–7.View ArticlePubMedGoogle Scholar
- Yao F, Schaffer PA. An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1. J Virol. 1995;69:6249–58.PubMedPubMed CentralGoogle Scholar
- Chisholm SE, Howard K, Gomez MV, Reyburn HT. Expression of ICP0 is sufficient to trigger natural killer cell recognition of herpes simplex virus-infected cells by natural cytotoxicity receptors. J Infect Dis. 2007;195:1160–8.View ArticlePubMedGoogle Scholar
- Boutell C, Everett RD. Herpes simplex virus type 1 infection induces the stabilization of p53 in a USP7- and ATM-independent manner. J Virol. 2004;78:8068–77.View ArticlePubMedPubMed CentralGoogle Scholar
- Huang CH, Yuan Q, Chen PJ, Zhang YL, Chen CR, Zheng QB, Yeh SH, Yu H, Xue Y, Chen YX, et al. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol. 2012;57:720–9.View ArticlePubMedGoogle Scholar
- Geng X, Huang C, Qin Y, McCombs JE, Yuan Q, Harry BL, Palmer AE, Xia NS, Xue D. Hepatitis B virus X protein targets Bcl-2 proteins to increase intracellular calcium, required for virus replication and cell death induction. Proc Natl Acad Sci U S A. 2012;109:18471–6.View ArticlePubMedPubMed CentralGoogle Scholar